PMGC Capital LLC, a wholly-owned subsidiary of PMGC Holdings Inc., issued a public statement on June 18, 2025, urging Alaunos Therapeutics, Inc. (NASDAQ: TCRT) to accept a term sheet facilitated through a leading Wall Street Bank. PMGC Capital holds a significant ownership position in Alaunos.
The proposed financing, introduced by PMGC Capital and sent to Alaunos' board on May 25, 2025, represents a compelling, value-aligned opportunity. Braeden Lichti, CEO of Northstrive Companies Inc., Manager of PMGC Capital, described it as a non-toxic, well-structured offer providing substantial capital and potentially creating massive value for shareholders.
PMGC Capital remains committed to working constructively with Alaunos’ Board and management to maximize long-term value. It urges them to engage directly with the bank while the opportunity remains actionable, commending Alaunos for maintaining a clean capital structure.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.